Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation

L. L. Edwards, Zbigniew K Wszolek, M. M. Normand

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction - Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients. Methods - Our institution averages 35 allogeneic BMT's per year. In the past year we have seen two women with reversible cortical blindness secondary to CSA toxicity. Results - Age (years) (Case 1; Case 2): 32; 22. Day post-BMT: 41; 50. Peak CSA level (ng/ml): 1159; 632. Both had a history of renal toxicity requiring adjustment of CSA dosage. MRI - both with diffuse white matter changes. EEG-both with moderate to severe generalized slowing. Visual evoked potentials were markedly prolonged in both. Auditory evoked potentials: minimally abnormal; normal. Somatosensory evoked potentials - both normal. Prompt improvement occurred with discontinuation of CSA. Followup neurophysiologic evaluations were normal, however structural changes remained on MRI. Conclusion - As neurophysiologic studies closely follow the clinical status they should be included in the evaluation and followup of CSA neurotoxicity.

Original languageEnglish (US)
Pages (from-to)423-429
Number of pages7
JournalActa Neurologica Scandinavica
Volume92
Issue number5
StatePublished - 1995
Externally publishedYes

Fingerprint

Cortical Blindness
Bone Marrow Transplantation
Cyclosporine
Bone Marrow
Auditory Evoked Potentials
Somatosensory Evoked Potentials
Visual Evoked Potentials
Electroencephalography
Transplants
Kidney

Keywords

  • Bone marrow transplantation
  • Cyclosporine neurotoxicity
  • Neurophysiologic evaluation

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation. / Edwards, L. L.; Wszolek, Zbigniew K; Normand, M. M.

In: Acta Neurologica Scandinavica, Vol. 92, No. 5, 1995, p. 423-429.

Research output: Contribution to journalArticle

@article{edd33fda5bf4421681fef98d233d0a21,
title = "Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation",
abstract = "Introduction - Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients. Methods - Our institution averages 35 allogeneic BMT's per year. In the past year we have seen two women with reversible cortical blindness secondary to CSA toxicity. Results - Age (years) (Case 1; Case 2): 32; 22. Day post-BMT: 41; 50. Peak CSA level (ng/ml): 1159; 632. Both had a history of renal toxicity requiring adjustment of CSA dosage. MRI - both with diffuse white matter changes. EEG-both with moderate to severe generalized slowing. Visual evoked potentials were markedly prolonged in both. Auditory evoked potentials: minimally abnormal; normal. Somatosensory evoked potentials - both normal. Prompt improvement occurred with discontinuation of CSA. Followup neurophysiologic evaluations were normal, however structural changes remained on MRI. Conclusion - As neurophysiologic studies closely follow the clinical status they should be included in the evaluation and followup of CSA neurotoxicity.",
keywords = "Bone marrow transplantation, Cyclosporine neurotoxicity, Neurophysiologic evaluation",
author = "Edwards, {L. L.} and Wszolek, {Zbigniew K} and Normand, {M. M.}",
year = "1995",
language = "English (US)",
volume = "92",
pages = "423--429",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation

AU - Edwards, L. L.

AU - Wszolek, Zbigniew K

AU - Normand, M. M.

PY - 1995

Y1 - 1995

N2 - Introduction - Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients. Methods - Our institution averages 35 allogeneic BMT's per year. In the past year we have seen two women with reversible cortical blindness secondary to CSA toxicity. Results - Age (years) (Case 1; Case 2): 32; 22. Day post-BMT: 41; 50. Peak CSA level (ng/ml): 1159; 632. Both had a history of renal toxicity requiring adjustment of CSA dosage. MRI - both with diffuse white matter changes. EEG-both with moderate to severe generalized slowing. Visual evoked potentials were markedly prolonged in both. Auditory evoked potentials: minimally abnormal; normal. Somatosensory evoked potentials - both normal. Prompt improvement occurred with discontinuation of CSA. Followup neurophysiologic evaluations were normal, however structural changes remained on MRI. Conclusion - As neurophysiologic studies closely follow the clinical status they should be included in the evaluation and followup of CSA neurotoxicity.

AB - Introduction - Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients. Methods - Our institution averages 35 allogeneic BMT's per year. In the past year we have seen two women with reversible cortical blindness secondary to CSA toxicity. Results - Age (years) (Case 1; Case 2): 32; 22. Day post-BMT: 41; 50. Peak CSA level (ng/ml): 1159; 632. Both had a history of renal toxicity requiring adjustment of CSA dosage. MRI - both with diffuse white matter changes. EEG-both with moderate to severe generalized slowing. Visual evoked potentials were markedly prolonged in both. Auditory evoked potentials: minimally abnormal; normal. Somatosensory evoked potentials - both normal. Prompt improvement occurred with discontinuation of CSA. Followup neurophysiologic evaluations were normal, however structural changes remained on MRI. Conclusion - As neurophysiologic studies closely follow the clinical status they should be included in the evaluation and followup of CSA neurotoxicity.

KW - Bone marrow transplantation

KW - Cyclosporine neurotoxicity

KW - Neurophysiologic evaluation

UR - http://www.scopus.com/inward/record.url?scp=0028822587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028822587&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 423

EP - 429

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 5

ER -